Hoskin, P., Sartor, O., O'Sullivan, JM., Johannessen, DC., Helle, SI., Logue, J., Bottomley, D., Nilsson, S., Vogelzang, NJ., et al. (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without prior docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol, Vol.15, pp.1397–1406, Show Abstract      

Sartor, O., Coleman, R., Nilsson, S., Heinrich, D., Helle, SI., O'Sullivan, JM., Fosså, SD., Chodacki, A., Wiechno, P., Logue, J., Widmark, A., et al. (2014) Effect of radium-223 on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double blind, randomised trial. Lancet Oncol, Vol.15, pp.738–746, Show Abstract

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. (2013) N Engl J Med, Vol.369, pp.213–223, Show Abstract